Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy a...
Saved in:
| Published in | Experimental & molecular medicine Vol. 54; no. 9; pp. 1379 - 1389 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.09.2022
Springer Nature B.V 생화학분자생물학회 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications.
Cancer therapy: Interrupting messages sent by tumors
Inhibiting or removing tumor-derived exosomes (TDEs), tiny membrane-bound packets of DNA, RNA, and proteins secreted by tumors, may improve cancer therapies. TDEs can suppress the body’s immune response, promote tumor progression and spread, and reduce efficacy of cancer drugs and immunotherapy. Gang Chen at Wuhan University, China, and co-workers have reviewed ways to remove or inhibit production of TDEs. They report that disruption of the genes for production of TDEs, drugs that inhibit TDE secretion, and removal of TDEs via plasma exchange or dialysis are all being investigated and show promise for reducing patient TDE load, thereby increasing the efficacy of anti-cancer drugs and immunotherapy. Future challenges include reducing side effects and finding less invasive ways to filter out TDEs. Gaining a better understanding of TDEs may help to improve therapies for many types of cancer. |
|---|---|
| AbstractList | Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications. KCI Citation Count: 0 Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications.Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications. Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications.Cancer therapy: Interrupting messages sent by tumorsInhibiting or removing tumor-derived exosomes (TDEs), tiny membrane-bound packets of DNA, RNA, and proteins secreted by tumors, may improve cancer therapies. TDEs can suppress the body’s immune response, promote tumor progression and spread, and reduce efficacy of cancer drugs and immunotherapy. Gang Chen at Wuhan University, China, and co-workers have reviewed ways to remove or inhibit production of TDEs. They report that disruption of the genes for production of TDEs, drugs that inhibit TDE secretion, and removal of TDEs via plasma exchange or dialysis are all being investigated and show promise for reducing patient TDE load, thereby increasing the efficacy of anti-cancer drugs and immunotherapy. Future challenges include reducing side effects and finding less invasive ways to filter out TDEs. Gaining a better understanding of TDEs may help to improve therapies for many types of cancer. Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications. Cancer therapy: Interrupting messages sent by tumors Inhibiting or removing tumor-derived exosomes (TDEs), tiny membrane-bound packets of DNA, RNA, and proteins secreted by tumors, may improve cancer therapies. TDEs can suppress the body’s immune response, promote tumor progression and spread, and reduce efficacy of cancer drugs and immunotherapy. Gang Chen at Wuhan University, China, and co-workers have reviewed ways to remove or inhibit production of TDEs. They report that disruption of the genes for production of TDEs, drugs that inhibit TDE secretion, and removal of TDEs via plasma exchange or dialysis are all being investigated and show promise for reducing patient TDE load, thereby increasing the efficacy of anti-cancer drugs and immunotherapy. Future challenges include reducing side effects and finding less invasive ways to filter out TDEs. Gaining a better understanding of TDEs may help to improve therapies for many types of cancer. Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications. Inhibiting or removing tumor-derived exosomes (TDEs), tiny membrane-bound packets of DNA, RNA, and proteins secreted by tumors, may improve cancer therapies. TDEs can suppress the body’s immune response, promote tumor progression and spread, and reduce efficacy of cancer drugs and immunotherapy. Gang Chen at Wuhan University, China, and co-workers have reviewed ways to remove or inhibit production of TDEs. They report that disruption of the genes for production of TDEs, drugs that inhibit TDE secretion, and removal of TDEs via plasma exchange or dialysis are all being investigated and show promise for reducing patient TDE load, thereby increasing the efficacy of anti-cancer drugs and immunotherapy. Future challenges include reducing side effects and finding less invasive ways to filter out TDEs. Gaining a better understanding of TDEs may help to improve therapies for many types of cancer. Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications. |
| Author | Li, Ye Wang, Kui-Ming Chen, Gang Chen, Zhuo-Kun Zhang, He-Jing Duan, Xu Xiao, Bo-Lin |
| Author_xml | – sequence: 1 givenname: Ye surname: Li fullname: Li, Ye organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University – sequence: 2 givenname: Zhuo-Kun surname: Chen fullname: Chen, Zhuo-Kun organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 3 givenname: Xu surname: Duan fullname: Duan, Xu organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 4 givenname: He-Jing surname: Zhang fullname: Zhang, He-Jing organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 5 givenname: Bo-Lin surname: Xiao fullname: Xiao, Bo-Lin organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 6 givenname: Kui-Ming surname: Wang fullname: Wang, Kui-Ming organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 7 givenname: Gang orcidid: 0000-0003-3332-3511 surname: Chen fullname: Chen, Gang email: geraldchan@whu.edu.cn organization: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, TaiKang Center for Life and Medical Sciences, Wuhan University, Frontier Science Center for Immunology and Metabolism, Wuhan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36117219$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002881580$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9Ul1rFDEUDVKxH_oHfJABX0QYzedk5kUoxY9CQZDV15DJ3OymnUnWJLPovze702rtQ0ngBu45h3Nvzik68sEDQi8Jfkcwa98nQqlsakxpjXErmpo9QScUd7RuOGFH997H6DSla4yp4JI_Q8esIURS0p2gHysd15BhqJzfuN5lF3wVbJXnKcR6gOh2pQe_QgoTpEqXW_mwg7HKG4h6C3N2pgrbA8-GWBntDcTn6KnVY4IXt_UMff_0cXXxpb76-vny4vyqNkKKXAOjPRGM4a6HdrBUGKspkb0wrWa9BmutwKKMBppjKnFnWs5Jzwcp-GCkYGfo7aLro1U3xqmg3aGug7qJ6vzb6lIRjAXmTVPAHxbwdu4nGAz4HPWottFNOv4-UP_veLcpQjvVCcbbVhaBN7cCMfycIWU1uWRgHLWHMCdFJRGyI2XLBfr6AfQ6zNGXXRQUJbwpZ2__1X1Hf63c_U8BtAvAxJBSBKuMy3q_7GLQjWU2tY-CWqKgShTUIQqKFSp9QL1Tf5TEFlIqYL-G-M_2I6w_xyPF9w |
| CitedBy_id | crossref_primary_10_1016_j_apsb_2025_03_007 crossref_primary_10_1016_j_jpha_2023_12_010 crossref_primary_10_1016_j_jconrel_2025_02_066 crossref_primary_10_1016_j_bbcan_2023_188867 crossref_primary_10_1016_j_critrevonc_2023_103967 crossref_primary_10_1016_j_gene_2023_147726 crossref_primary_10_3390_ijms252111433 crossref_primary_10_1016_j_canlet_2025_217636 crossref_primary_10_1021_acsami_3c03233 crossref_primary_10_3389_fimmu_2024_1473030 crossref_primary_10_3390_ijms25010255 crossref_primary_10_1002_advs_202304222 crossref_primary_10_1016_j_ymthe_2024_08_027 crossref_primary_10_1111_jcmm_18138 crossref_primary_10_3389_fonc_2024_1349474 crossref_primary_10_1002_advs_202307338 crossref_primary_10_1016_j_canlet_2023_216077 crossref_primary_10_1620_tjem_2024_J082 crossref_primary_10_1038_s41421_024_00743_3 crossref_primary_10_1002_jrs_6767 crossref_primary_10_3389_fbioe_2024_1363742 crossref_primary_10_1016_j_canlet_2024_216759 crossref_primary_10_3390_pharmaceutics16111439 crossref_primary_10_1186_s41232_024_00358_x crossref_primary_10_1016_j_prp_2023_155083 crossref_primary_10_1111_pin_13459 crossref_primary_10_1186_s12967_024_05267_8 crossref_primary_10_1016_j_bbrc_2024_150066 crossref_primary_10_1186_s12935_024_03312_6 crossref_primary_10_15789_1563_0625_NSF_2938 crossref_primary_10_1016_j_intimp_2025_114176 crossref_primary_10_3390_ijms24031968 crossref_primary_10_1016_j_addr_2023_115028 crossref_primary_10_3390_cancers15020501 crossref_primary_10_1080_15384047_2024_2356831 crossref_primary_10_3389_fonc_2024_1459178 crossref_primary_10_1016_j_tcb_2024_08_008 crossref_primary_10_1016_j_ejmech_2025_117278 crossref_primary_10_3389_fimmu_2023_1265101 crossref_primary_10_3390_pharmaceutics15082042 crossref_primary_10_4155_tde_2023_0131 crossref_primary_10_3892_ijo_2024_5706 crossref_primary_10_1002_advs_202417357 crossref_primary_10_1002_advs_202415133 crossref_primary_10_1016_j_engmed_2024_100023 crossref_primary_10_1038_s41541_024_01035_3 |
| Cites_doi | 10.1016/j.immuni.2018.03.007 10.1016/j.canlet.2019.01.017 10.1038/s41598-018-26411-7 10.3402/jev.v4.27066 10.1158/0008-5472.CAN-18-3962 10.1038/nrg2988 10.1038/nrm2728 10.1186/1476-4598-13-88 10.1080/2162402X.2017.1362527 10.1016/bs.acc.2015.12.005 10.1074/jbc.M210843200 10.1007/s13277-014-2377-z 10.1016/j.jbior.2014.10.002 10.3390/cells8070727 10.3389/fonc.2021.611081 10.1186/s12943-019-0991-5 10.1016/j.cell.2011.03.054 10.1016/j.semcancer.2019.02.004 10.3390/ijms22126234 10.1083/jcb.201110031 10.1007/s13277-016-5071-5 10.1038/s41467-019-09387-4 10.1155/2014/179486 10.1038/emboj.2011.286 10.1186/s12885-015-2025-z 10.3390/cells9040861 10.1002/jev2.12146 10.1016/j.ijbiomac.2021.07.110 10.1007/978-3-030-43085-6_13 10.1016/j.humpath.2015.09.046 10.1021/acs.langmuir.0c03613 10.1016/j.bbamcr.2007.04.015 10.1038/ncb1800 10.1038/s41389-017-0022-6 10.1016/j.cell.2016.03.031 10.1016/j.yexcr.2020.111983 10.1074/mcp.M900381-MCP200 10.1080/20013078.2017.1368823 10.1007/s12035-020-02231-7 10.1016/j.celrep.2013.10.050 10.1038/s41577-019-0167-y 10.1158/0008-5472.CAN-19-3682 10.1016/j.molcel.2015.04.028 10.1126/sciadv.aba5210 10.1021/acs.analchem.0c02006 10.1080/20013078.2019.1703244 10.1074/jbc.M115.679217 10.1016/j.arcmed.2020.10.018 10.1038/nature22396 10.1038/nrd.2018.168 10.1016/j.bbcan.2018.07.003 10.1016/j.celrep.2018.06.066 10.1158/0008-5472.CAN-13-3512 10.1083/jcb.201601025 10.3390/molecules26082380 10.1002/jev2.12218 10.1016/j.canlet.2017.08.020 10.1038/onc.2017.134 10.1194/jlr.R084343 10.1038/nrg3899 10.1111/cas.15225 10.1016/j.canlet.2016.01.043 10.1016/j.apsb.2021.05.020 10.1126/sciadv.aar2766 10.3389/fonc.2020.00472 10.1111/cas.13310 10.1038/srep42961 10.1080/21691401.2021.1902337 10.1158/0008-5472.CAN-17-3841 10.2217/fon-2017-0343 10.1038/s41467-018-07810-w 10.1002/jca.21781 10.1038/ncomms13588 10.1042/BST20120265 10.1089/nat.2019.0790 10.1007/s10555-021-09962-6 10.1038/nature15756 10.1038/s41568-019-0238-1 10.1038/ncomms4477 10.1016/j.cell.2019.02.016 10.1038/ncomms14041 10.1073/pnas.1705134114 10.3390/ijms21165840 10.3390/ijms23031461 10.1126/science.1153124 10.1016/j.bbamcr.2009.09.011 10.1083/jcb.201211138 10.1016/j.canlet.2019.11.009 10.1111/cei.12354 10.1038/s41388-019-1014-0 10.1038/ncb2502 10.1038/s41598-021-89655-w 10.3892/ijo.2016.3560 10.1083/jcb.201904113 10.3390/jcm9020436 10.1016/j.tcb.2013.09.006 10.1136/jitc-2020-001113 10.1038/nature08849 10.1126/science.aau6977 10.1007/s40472-017-0157-6 10.1186/s12943-019-0975-5 10.1016/j.drudis.2019.06.014 10.1080/14728222.2018.1464141 10.1038/nrg3742 10.1016/j.semcdb.2017.01.004 10.1158/0008-5472.CAN-10-1722 10.4049/jimmunol.176.3.1375 10.1158/1541-7786.MCR-17-0784 10.1126/science.1161748 10.1038/s41422-018-0060-4 10.1007/s40259-017-0234-5 10.18632/oncotarget.9862 10.1093/abbs/gmab038 10.1158/1541-7786.MCR-18-0358 10.1038/srep20254 10.1016/j.trecan.2020.03.002 10.1038/nchembio.1793 10.1074/jbc.M109.041152 10.1016/j.semcdb.2017.08.022 10.1158/0008-5472.CAN-06-2756 10.1038/ncb2000 10.1038/nbt.3437 10.1038/s41467-021-25990-w 10.1016/j.bcmd.2005.07.001 10.1080/21541248.2016.1264352 10.1038/nrc.2016.73 10.1126/science.aar4060 10.1038/s41422-020-00409-1 10.1038/s41586-018-0392-8 10.1016/j.celrep.2013.10.019 10.1002/mc.23129 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM ACYCR |
| DOI | 10.1038/s12276-022-00856-3 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals (WRLC) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 2092-6413 |
| EndPage | 1389 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10050466 PMC9534887 36117219 10_1038_s12276_022_00856_3 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 81922038 funderid: https://doi.org/10.13039/501100001809 – fundername: China Postdoctoral Science Foundation grantid: 2021M692474 funderid: https://doi.org/10.13039/501100002858 – fundername: ; grantid: 81922038 – fundername: ; grantid: 2021M692474 |
| GroupedDBID | --- 0R~ 29G 2WC 3V. 5-W 53G 5GY 7X7 87B 88E 8FE 8FH 8FI 8FJ 8JR 9ZL AAJSJ ABUWG ACGFO ACGFS ACPRK ACSMW ACYCR ADBBV AENEX AFKRA AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI C1A C6C CCPQU DIK DU5 E3Z EBLON EBS EF. EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE LK8 M1P M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT TR2 UKHRP W2D XSB AASML AAYXX CITATION OVT PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c575t-e32b153309be8df25cfa217b5c8a3baefff505856ea402709c8441b4d754dc753 |
| IEDL.DBID | 7X7 |
| ISSN | 2092-6413 1226-3613 |
| IngestDate | Sun Mar 09 07:54:34 EDT 2025 Thu Aug 21 18:39:49 EDT 2025 Fri Jul 11 10:19:22 EDT 2025 Wed Aug 13 05:12:20 EDT 2025 Thu Apr 03 07:00:32 EDT 2025 Thu Apr 24 23:11:30 EDT 2025 Tue Jul 01 04:10:31 EDT 2025 Fri Feb 21 02:40:07 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c575t-e32b153309be8df25cfa217b5c8a3baefff505856ea402709c8441b4d754dc753 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-3332-3511 |
| OpenAccessLink | https://www.proquest.com/docview/2721464645?pq-origsite=%requestingapplication% |
| PMID | 36117219 |
| PQID | 2721464645 |
| PQPubID | 2041975 |
| PageCount | 11 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10050466 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9534887 proquest_miscellaneous_2715791254 proquest_journals_2721464645 pubmed_primary_36117219 crossref_citationtrail_10_1038_s12276_022_00856_3 crossref_primary_10_1038_s12276_022_00856_3 springer_journals_10_1038_s12276_022_00856_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: United States – name: Seoul |
| PublicationTitle | Experimental & molecular medicine |
| PublicationTitleAbbrev | Exp Mol Med |
| PublicationTitleAlternate | Exp Mol Med |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Springer Nature B.V 생화학분자생물학회 |
| Publisher_xml | – name: Nature Publishing Group UK – name: Springer Nature B.V – name: 생화학분자생물학회 |
| References | Zeng (CR10) 2018; 9 Kotterman, Schaffer (CR126) 2014; 15 Fujita (CR64) 2017; 7 Li, Nabet (CR44) 2019; 18 Wu (CR109) 2021; 187 Larios, Mercier, Roux, Gruenberg (CR69) 2020; 219 Wei (CR96) 2021; 31 Sasabe (CR108) 2022; 113 Yanez-Mo (CR1) 2015; 4 Muller, Mitsuhashi, Simms, Gooding, Whiteside (CR19) 2016; 6 Naso, Tomkowicz, Perry, Strohl (CR120) 2017; 31 Behr, Zhou, Xu, Zhang (CR119) 2021; 11 Wu, Wu, Huang, Chang (CR114) 2021; 37 Hoshino (CR93) 2013; 5 Chen (CR52) 2018; 560 Wang (CR101) 2021; 12 Zeng (CR48) 2017; 36 Shamseddine, Airola, Hannun (CR97) 2015; 57 Vakulskas, Behlke (CR118) 2019; 29 Tayebi, Zhou, Tripathi, Chandramohanadas, Ai (CR115) 2020; 92 Cheng (CR29) 2021; 52 Lv (CR47) 2014; 35 Im (CR110) 2019; 10 Lei (CR13) 2020; 470 Whiteside (CR11) 2016; 74 Hong, Lev (CR80) 2014; 24 Kalluri (CR32) 2016; 16 Hinshaw, Shevde (CR14) 2019; 79 Lu (CR134) 2022; 11 Sung (CR35) 2020; 39 Wolf-Dennen, Kleinerman (CR9) 2020; 1258 Ruiz-Martinez (CR82) 2016; 7 Liu (CR22) 2006; 176 Tschuschke (CR103) 2020; 9 Orme (CR112) 2020; 8 Catalano, O’Driscoll (CR127) 2020; 9 Raposo, Stoorvogel (CR4) 2013; 200 Trajkovic (CR72) 2008; 319 Shalem, Sanjana, Zhang (CR125) 2015; 16 Datta (CR105) 2017; 408 Yang (CR36) 2020; 391 Wei (CR88) 2017; 8 Colombo (CR66) 2013; 126 Huotari, Helenius (CR56) 2011; 30 Dores (CR70) 2012; 197 Whiteside (CR21) 2017; 13 Xi (CR85) 2021; 10 Wang (CR28) 2018; 78 Webber, Steadman, Mason, Tabi, Clayton (CR33) 2010; 70 Deng (CR61) 2021; 11 Lobb, Lima, Moller (CR12) 2017; 67 Whiteside (CR17) 2013; 41 Toyoshima (CR60) 2007; 67 Zhu (CR63) 2021; 58 Stenmark (CR74) 2009; 10 Montermini (CR99) 2015; 290 Mashouri (CR5) 2019; 18 Li (CR46) 2016; 49 Wu (CR27) 2016; 37 Prior, Hood, Hartley (CR89) 2020; 80 Wu, Dai (CR84) 2017; 387 Wollert, Hurley (CR58) 2010; 464 Ma (CR131) 2020; 35 Lemke (CR132) 2019; 19 Wang (CR113) 2021; 49 Gordon (CR133) 2017; 545 Zhang (CR23) 2007; 1773 Abrami (CR78) 2013; 5 Zhao (CR65) 2016; 52 Guo (CR45) 2020; 10 Li (CR124) 2021; 26 Whiteside, Diergaarde, Hong (CR6) 2021; 22 Mingozzi, High (CR121) 2011; 12 Shin (CR111) 2022; 9 Doench (CR123) 2016; 34 Sinha (CR95) 2016; 214 Hoshino (CR7) 2015; 527 Fader, Sánchez, Mestre, Colombo (CR83) 2009; 1793 Ribas, Wolchok (CR49) 2018; 359 Roma-Rodrigues, Fernandes, Baptista (CR30) 2014; 2014 Monypenny (CR71) 2018; 24 Miyazaki, Ikeda, Sato, Horie-Inoue, Inoue (CR18) 2018; 7 Ringuette Goulet (CR34) 2018; 16 Boettcher, McManus (CR92) 2015; 58 Schuler (CR20) 2014; 177 Skog (CR38) 2008; 10 Ricklefs (CR54) 2018; 4 Peak (CR81) 2020; 59 Ekstrom (CR41) 2014; 13 Juan, Fürthauer (CR57) 2018; 74 Minn, Wherry (CR50) 2016; 165 Olejarz, Kubiak-Tomaszewska, Chrzanowska, Lorenc (CR40) 2020; 21 Ostrowski (CR76) 2010; 12 Grange (CR26) 2015; 15 Airola (CR102) 2017; 114 Parvathaneni, Kulkarni, Muth, Gupta (CR129) 2019; 24 Blanc, Vidal (CR75) 2018; 9 Patel, Minn (CR51) 2018; 48 Morrissey, Yan (CR55) 2020; 6 Davis, Pattanayak, Thompson, Zuris, Liu (CR122) 2015; 11 Kalluri, LeBleu (CR2) 2020; 367 Matsumoto (CR100) 2017; 108 Chen (CR116) 2019; 447 Sahai (CR31) 2020; 20 Luo (CR87) 2011; 145 Yang (CR98) 2018; 28 Pushpakom (CR128) 2019; 18 Poggio (CR53) 2019; 177 Im (CR130) 2019; 10 Sexton, Mpilla, Kim, Philip, Azmi (CR90) 2019; 54 Doyle, Wang (CR3) 2019; 8 Ostenfeld (CR77) 2014; 74 Park (CR39) 2010; 9 Datta (CR106) 2018; 8 Kim (CR8) 2020; 9 Yang (CR62) 2021; 53 Jouida, McCarthy, Fabre, Keane (CR91) 2021; 40 Ludwig, Yerneni, Razzo, Whiteside (CR37) 2018; 16 Baietti (CR68) 2012; 14 Skotland, Hessvik, Sandvig, Llorente (CR73) 2019; 60 Hao, Wu, Wu, Wang, Vadgama (CR16) 2022; 23 Namee, O’Driscoll (CR43) 2018; 1870 Greenberg (CR107) 2021; 11 Parolini (CR86) 2009; 284 Salimu (CR24) 2017; 6 Mourad, Gianello (CR117) 2017; 4 Ludwig, Whiteside (CR42) 2018; 22 Yoo (CR104) 2020; 6 Abusamra (CR15) 2005; 35 Südhof, Rothman (CR79) 2009; 323 Ghossoub (CR94) 2014; 5 Villarroya-Beltri (CR59) 2016; 7 Shen (CR25) 2017; 6 Bache, Raiborg, Mehlum, Stenmark (CR67) 2003; 278 FL Ricklefs (856_CR54) 2018; 4 Y Wei (856_CR88) 2017; 8 M Colombo (856_CR66) 2013; 126 G Wang (856_CR101) 2021; 12 SM Morrissey (856_CR55) 2020; 6 MV Airola (856_CR102) 2017; 114 C Grange (856_CR26) 2015; 15 T Peak (856_CR81) 2020; 59 CM Fader (856_CR83) 2009; 1793 X Lei (856_CR13) 2020; 470 J Skog (856_CR38) 2008; 10 J Orme (856_CR112) 2020; 8 R Kalluri (856_CR2) 2020; 367 J Webber (856_CR33) 2010; 70 M Chen (856_CR116) 2019; 447 Y Shen (856_CR25) 2017; 6 T Südhof (856_CR79) 2009; 323 G Raposo (856_CR4) 2013; 200 Y Zhu (856_CR63) 2021; 58 EJ Im (856_CR110) 2019; 10 R Ghossoub (856_CR94) 2014; 5 AL Zeng (856_CR48) 2017; 36 G Chen (856_CR52) 2018; 560 TL Whiteside (856_CR21) 2017; 13 MM Lv (856_CR47) 2014; 35 JS Sung (856_CR35) 2020; 39 C Villarroya-Beltri (856_CR59) 2016; 7 J Larios (856_CR69) 2020; 219 S Sinha (856_CR95) 2016; 214 AJ Abusamra (856_CR15) 2005; 35 TL Whiteside (856_CR17) 2013; 41 E Sahai (856_CR31) 2020; 20 N Ludwig (856_CR37) 2018; 16 M Ostrowski (856_CR76) 2010; 12 D Wei (856_CR96) 2021; 31 A Jouida (856_CR91) 2021; 40 L Wang (856_CR113) 2021; 49 L Xi (856_CR85) 2021; 10 SA Patel (856_CR51) 2018; 48 X Wu (856_CR109) 2021; 187 E Sasabe (856_CR108) 2022; 113 M Behr (856_CR119) 2021; 11 L Mashouri (856_CR5) 2019; 18 M Ruiz-Martinez (856_CR82) 2016; 7 L Blanc (856_CR75) 2018; 9 L Muller (856_CR19) 2016; 6 W Hong (856_CR80) 2014; 24 DC Hinshaw (856_CR14) 2019; 79 J Huotari (856_CR56) 2011; 30 J Monypenny (856_CR71) 2018; 24 T Miyazaki (856_CR18) 2018; 7 EJ Ekstrom (856_CR41) 2014; 13 J Li (856_CR46) 2016; 49 Y Yang (856_CR98) 2018; 28 W Olejarz (856_CR40) 2020; 21 C Ringuette Goulet (856_CR34) 2018; 16 NM Namee (856_CR43) 2018; 1870 L Montermini (856_CR99) 2015; 290 A Ribas (856_CR49) 2018; 359 K Trajkovic (856_CR72) 2008; 319 L Wu (856_CR27) 2016; 37 G Lemke (856_CR132) 2019; 19 Q Hao (856_CR16) 2022; 23 T Deng (856_CR61) 2021; 11 T Lu (856_CR134) 2022; 11 PJ Schuler (856_CR20) 2014; 177 M Tayebi (856_CR115) 2020; 92 T Wollert (856_CR58) 2010; 464 JM Shin (856_CR111) 2022; 9 A Datta (856_CR105) 2017; 408 X Wang (856_CR28) 2018; 78 C Liu (856_CR22) 2006; 176 RE Sexton (856_CR90) 2019; 54 QR Guo (856_CR45) 2020; 10 T Skotland (856_CR73) 2019; 60 MF Naso (856_CR120) 2017; 31 I Li (856_CR44) 2019; 18 HG Zhang (856_CR23) 2007; 1773 Y Yang (856_CR62) 2021; 53 L Abrami (856_CR78) 2013; 5 E Im (856_CR130) 2019; 10 Z Cheng (856_CR29) 2021; 52 H Stenmark (856_CR74) 2009; 10 M Yanez-Mo (856_CR1) 2015; 4 LM Doyle (856_CR3) 2019; 8 IA Prior (856_CR89) 2020; 80 TL Whiteside (856_CR6) 2021; 22 SS Yang (856_CR36) 2020; 391 MR Dores (856_CR70) 2012; 197 J Salimu (856_CR24) 2017; 6 AJ Minn (856_CR50) 2016; 165 M Poggio (856_CR53) 2019; 177 I Parolini (856_CR86) 2009; 284 KG Bache (856_CR67) 2003; 278 JG Doench (856_CR123) 2016; 34 S Pushpakom (856_CR128) 2019; 18 N Ludwig (856_CR42) 2018; 22 K Fujita (856_CR64) 2017; 7 M Boettcher (856_CR92) 2015; 58 F Mingozzi (856_CR121) 2011; 12 M Tschuschke (856_CR103) 2020; 9 A Hoshino (856_CR7) 2015; 527 JW Greenberg (856_CR107) 2021; 11 V Parvathaneni (856_CR129) 2019; 24 CA Vakulskas (856_CR118) 2019; 29 D Li (856_CR124) 2021; 26 SW Yoo (856_CR104) 2020; 6 TL Whiteside (856_CR11) 2016; 74 K Wolf-Dennen (856_CR9) 2020; 1258 C Zhao (856_CR65) 2016; 52 MA Kotterman (856_CR126) 2014; 15 M Toyoshima (856_CR60) 2007; 67 M Baietti (856_CR68) 2012; 14 D Hoshino (856_CR93) 2013; 5 C Roma-Rodrigues (856_CR30) 2014; 2014 JE Park (856_CR39) 2010; 9 H Kim (856_CR8) 2020; 9 AA Shamseddine (856_CR97) 2015; 57 Z Zeng (856_CR10) 2018; 9 W Luo (856_CR87) 2011; 145 M Catalano (856_CR127) 2020; 9 RJ Lobb (856_CR12) 2017; 67 O Shalem (856_CR125) 2015; 16 MS Ostenfeld (856_CR77) 2014; 74 A Datta (856_CR106) 2018; 8 T Wu (856_CR84) 2017; 387 KM Davis (856_CR122) 2015; 11 R Kalluri (856_CR32) 2016; 16 T Juan (856_CR57) 2018; 74 NI Mourad (856_CR117) 2017; 4 C Ma (856_CR131) 2020; 35 T Wu (856_CR114) 2021; 37 SR Gordon (856_CR133) 2017; 545 A Matsumoto (856_CR100) 2017; 108 |
| References_xml | – volume: 48 start-page: 417 year: 2018 end-page: 433 ident: CR51 article-title: Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies publication-title: Immunity doi: 10.1016/j.immuni.2018.03.007 – volume: 447 start-page: 48 year: 2019 end-page: 55 ident: CR116 article-title: CRISPR-Cas9 for cancer therapy: opportunities and challenges publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.01.017 – volume: 8 year: 2018 ident: CR106 article-title: High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: a drug repurposing strategy for advanced cancer publication-title: Sci. Rep. doi: 10.1038/s41598-018-26411-7 – volume: 4 start-page: 27066 year: 2015 ident: CR1 article-title: Biological properties of extracellular vesicles and their physiological functions publication-title: J. Extracell. Vesicles doi: 10.3402/jev.v4.27066 – volume: 79 start-page: 4557 year: 2019 end-page: 4566 ident: CR14 article-title: The tumor microenvironment innately modulates cancer progression publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3962 – volume: 12 start-page: 341 year: 2011 end-page: 355 ident: CR121 article-title: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges publication-title: Nat. Rev. Genet. doi: 10.1038/nrg2988 – volume: 10 start-page: 513 year: 2009 end-page: 525 ident: CR74 article-title: Rab GTPases as coordinators of vesicle traffic publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm2728 – volume: 13 year: 2014 ident: CR41 article-title: WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells publication-title: Mol. Cancer doi: 10.1186/1476-4598-13-88 – volume: 6 start-page: e1362527 year: 2017 ident: CR25 article-title: Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72/HSP105-TLR2/TLR4 pathway publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1362527 – volume: 74 start-page: 103 year: 2016 end-page: 141 ident: CR11 article-title: Tumor-derived exosomes and their role in cancer progression publication-title: Adv. Clin. Chem. doi: 10.1016/bs.acc.2015.12.005 – volume: 278 start-page: 12513 year: 2003 end-page: 12521 ident: CR67 article-title: STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes publication-title: J. Biol. Chem. doi: 10.1074/jbc.M210843200 – volume: 35 start-page: 10773 year: 2014 end-page: 10779 ident: CR47 article-title: Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein publication-title: Tumour Biol. doi: 10.1007/s13277-014-2377-z – volume: 57 start-page: 24 year: 2015 end-page: 41 ident: CR97 article-title: Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes publication-title: Adv. Biol. Regul. doi: 10.1016/j.jbior.2014.10.002 – volume: 8 start-page: 727 year: 2019 ident: CR3 article-title: Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis publication-title: Cells doi: 10.3390/cells8070727 – volume: 11 start-page: 611081 year: 2021 ident: CR61 article-title: STAM prolongs clear cell renal cell carcinoma patients’ survival via inhibiting cell growth and invasion publication-title: Front. Oncol. doi: 10.3389/fonc.2021.611081 – volume: 18 year: 2019 ident: CR5 article-title: Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance publication-title: Mol. Cancer doi: 10.1186/s12943-019-0991-5 – volume: 145 start-page: 732 year: 2011 end-page: 744 ident: CR87 article-title: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 publication-title: Cell doi: 10.1016/j.cell.2011.03.054 – volume: 54 start-page: 131 year: 2019 end-page: 137 ident: CR90 article-title: Ras and exosome signaling publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.02.004 – volume: 22 start-page: 6234 year: 2021 ident: CR6 article-title: Tumor-derived exosomes (TEX) and their role in immuno-oncology publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22126234 – volume: 197 start-page: 407 year: 2012 end-page: 419 ident: CR70 article-title: ALIX binds a YPX(3)L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sorting publication-title: J. Cell Biol. doi: 10.1083/jcb.201110031 – volume: 37 start-page: 12169 year: 2016 end-page: 12180 ident: CR27 article-title: Exosomes derived from gastric cancer cells activate NF-kappaB pathway in macrophages to promote cancer progression publication-title: Tumour Biol. doi: 10.1007/s13277-016-5071-5 – volume: 10 year: 2019 ident: CR110 article-title: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A publication-title: Nat. Commun. doi: 10.1038/s41467-019-09387-4 – volume: 2014 start-page: 179486 year: 2014 ident: CR30 article-title: Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells publication-title: Biomed. Res. Int. doi: 10.1155/2014/179486 – volume: 30 start-page: 3481 year: 2011 end-page: 3500 ident: CR56 article-title: Endosome maturation publication-title: Embo J. doi: 10.1038/emboj.2011.286 – volume: 15 year: 2015 ident: CR26 article-title: Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation publication-title: BMC Cancer doi: 10.1186/s12885-015-2025-z – volume: 9 start-page: e2103245 year: 2022 ident: CR111 article-title: Sulfisoxazole elicits robust antitumour immune response along with immune checkpoint therapy by inhibiting exosomal PD-L1 publication-title: Adv. Sci. (Weinh.) – volume: 9 start-page: 861 year: 2020 ident: CR8 article-title: The emerging roles of exosomes as EMT regulators in cancer publication-title: Cells doi: 10.3390/cells9040861 – volume: 10 start-page: e12146 year: 2021 ident: CR85 article-title: Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion publication-title: J. Extracell. Vesicles doi: 10.1002/jev2.12146 – volume: 187 start-page: 481 year: 2021 end-page: 491 ident: CR109 article-title: Heparan sulfate analogues regulate tumor-derived exosome formation that attenuates exosome functions in tumor processes publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2021.07.110 – volume: 1258 start-page: 189 year: 2020 end-page: 197 ident: CR9 article-title: Exosomes: dynamic mediators of extracellular communication in the tumor microenvironment publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-030-43085-6_13 – volume: 52 start-page: 110 year: 2016 end-page: 118 ident: CR65 article-title: The role of Alix in the proliferation of human glioma cells publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2015.09.046 – volume: 37 start-page: 3399 year: 2021 end-page: 3409 ident: CR114 article-title: Anticlogging hemofiltration device for mass collection of circulating tumor cells by ligand-free size selection publication-title: Langmuir doi: 10.1021/acs.langmuir.0c03613 – volume: 1773 start-page: 1116 year: 2007 end-page: 1123 ident: CR23 article-title: Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2007.04.015 – volume: 10 start-page: 1470 year: 2008 end-page: 1476 ident: CR38 article-title: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers publication-title: Nat. Cell. Biol. doi: 10.1038/ncb1800 – volume: 7 year: 2018 ident: CR18 article-title: Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression publication-title: Oncogenesis doi: 10.1038/s41389-017-0022-6 – volume: 165 start-page: 272 year: 2016 end-page: 275 ident: CR50 article-title: Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling publication-title: Cell doi: 10.1016/j.cell.2016.03.031 – volume: 391 start-page: 111983 year: 2020 ident: CR36 article-title: Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2020.111983 – volume: 9 start-page: 1085 year: 2010 end-page: 1099 ident: CR39 article-title: Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes publication-title: Mol. Cell Proteom. doi: 10.1074/mcp.M900381-MCP200 – volume: 6 start-page: 1368823 year: 2017 ident: CR24 article-title: Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes publication-title: J. Extracell. Vesicles doi: 10.1080/20013078.2017.1368823 – volume: 58 start-page: 2118 year: 2021 end-page: 2132 ident: CR63 article-title: TSG101 promotes the proliferation, migration, and invasion of human glioma cells by regulating the AKT/GSK3beta/beta-Catenin and RhoC/Cofilin pathways publication-title: Mol. Neurobiol. doi: 10.1007/s12035-020-02231-7 – volume: 5 start-page: 1159 year: 2013 end-page: 1168 ident: CR93 article-title: Exosome secretion is enhanced by invadopodia and drives invasive behavior publication-title: Cell Rep. doi: 10.1016/j.celrep.2013.10.050 – volume: 19 start-page: 539 year: 2019 end-page: 549 ident: CR132 article-title: How macrophages deal with death publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0167-y – volume: 80 start-page: 2969 year: 2020 end-page: 2974 ident: CR89 article-title: The frequency of Ras mutations in cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-19-3682 – volume: 58 start-page: 575 year: 2015 end-page: 585 ident: CR92 article-title: Choosing the right tool for the job: RNAi, TALEN, or CRISPR publication-title: Mol. Cell. doi: 10.1016/j.molcel.2015.04.028 – volume: 6 start-page: eaba5210 year: 2020 ident: CR104 article-title: Inhibition of neutral sphingomyelinase 2 promotes remyelination publication-title: Sci. Adv. doi: 10.1126/sciadv.aba5210 – volume: 92 start-page: 10733 year: 2020 end-page: 10742 ident: CR115 article-title: Exosome purification and analysis using a facile microfluidic hydrodynamic trapping device publication-title: Anal. Chem. doi: 10.1021/acs.analchem.0c02006 – volume: 9 start-page: 1703244 year: 2020 ident: CR127 article-title: Inhibiting extracellular vesicles formation and release: a review of EV inhibitors publication-title: J. Extracell. Vesicles doi: 10.1080/20013078.2019.1703244 – volume: 290 start-page: 24534 year: 2015 end-page: 24546 ident: CR99 article-title: Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content publication-title: J. Biol. Chem. doi: 10.1074/jbc.M115.679217 – volume: 52 start-page: 200 year: 2021 end-page: 210 ident: CR29 article-title: Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3 publication-title: Arch. Med. Res. doi: 10.1016/j.arcmed.2020.10.018 – volume: 545 start-page: 495 year: 2017 end-page: 499 ident: CR133 article-title: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity publication-title: Nature doi: 10.1038/nature22396 – volume: 18 start-page: 41 year: 2019 end-page: 58 ident: CR128 article-title: Drug repurposing: progress, challenges and recommendations publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.168 – volume: 1870 start-page: 123 year: 2018 end-page: 136 ident: CR43 article-title: Extracellular vesicles and anti-cancer drug resistance publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2018.07.003 – volume: 24 start-page: 630 year: 2018 end-page: 641 ident: CR71 article-title: ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.06.066 – volume: 74 start-page: 5758 year: 2014 end-page: 5771 ident: CR77 article-title: Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-3512 – volume: 214 start-page: 197 year: 2016 end-page: 213 ident: CR95 article-title: Cortactin promotes exosome secretion by controlling branched actin dynamics publication-title: J. Cell Biol. doi: 10.1083/jcb.201601025 – volume: 26 start-page: 2380 year: 2021 ident: CR124 article-title: Nanoparticles as drug delivery systems of RNAi in cancer therapy publication-title: Molecules doi: 10.3390/molecules26082380 – volume: 11 start-page: e12218 year: 2022 ident: CR134 article-title: CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment publication-title: J. Extracell. Vesicles doi: 10.1002/jev2.12218 – volume: 408 start-page: 73 year: 2017 end-page: 81 ident: CR105 article-title: Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells publication-title: Cancer Lett. doi: 10.1016/j.canlet.2017.08.020 – volume: 36 start-page: 5369 year: 2017 end-page: 5381 ident: CR48 article-title: Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma publication-title: Oncogene doi: 10.1038/onc.2017.134 – volume: 60 start-page: 9 year: 2019 end-page: 18 ident: CR73 article-title: Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology publication-title: J. Lipid Res. doi: 10.1194/jlr.R084343 – volume: 16 start-page: 299 year: 2015 end-page: 311 ident: CR125 article-title: High-throughput functional genomics using CRISPR-Cas9 publication-title: Nat. Rev. Genet. doi: 10.1038/nrg3899 – volume: 113 start-page: 609 year: 2022 end-page: 621 ident: CR108 article-title: Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis publication-title: Cancer Sci. doi: 10.1111/cas.15225 – volume: 387 start-page: 61 year: 2017 end-page: 68 ident: CR84 article-title: Tumor microenvironment and therapeutic response publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.01.043 – volume: 11 start-page: 2150 year: 2021 end-page: 2171 ident: CR119 article-title: In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges publication-title: Acta Pharm. Sin. B doi: 10.1016/j.apsb.2021.05.020 – volume: 4 start-page: eaar2766 year: 2018 ident: CR54 article-title: Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles publication-title: Sci. Adv. doi: 10.1126/sciadv.aar2766 – volume: 10 start-page: 472 year: 2020 ident: CR45 article-title: The role of exosomal microRNA in cancer drug resistance publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00472 – volume: 108 start-page: 1803 year: 2017 end-page: 1810 ident: CR100 article-title: Accelerated growth of B16BL6 tumor in mice through efficient uptake of their own exosomes by B16BL6 cells publication-title: Cancer Sci. doi: 10.1111/cas.13310 – volume: 7 year: 2017 ident: CR64 article-title: Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer publication-title: Sci. Rep. doi: 10.1038/srep42961 – volume: 49 start-page: 325 year: 2021 end-page: 334 ident: CR113 article-title: Targeting regulation of the tumour microenvironment induces apoptosis of breast cancer cells by an affinity hemoperfusion adsorbent publication-title: Artif. Cells Nanomed. Biotechnol. doi: 10.1080/21691401.2021.1902337 – volume: 78 start-page: 4586 year: 2018 end-page: 4598 ident: CR28 article-title: Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kgamma to promote pancreatic cancer metastasis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-3841 – volume: 13 start-page: 2583 year: 2017 end-page: 2592 ident: CR21 article-title: The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy publication-title: Future Oncol. doi: 10.2217/fon-2017-0343 – volume: 9 year: 2018 ident: CR10 article-title: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis publication-title: Nat. Commun. doi: 10.1038/s41467-018-07810-w – volume: 35 start-page: 206 year: 2020 end-page: 216 ident: CR131 article-title: Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica publication-title: J. Clin. Apher. doi: 10.1002/jca.21781 – volume: 7 year: 2016 ident: CR59 article-title: ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins publication-title: Nat. Commun. doi: 10.1038/ncomms13588 – volume: 41 start-page: 245 year: 2013 end-page: 251 ident: CR17 article-title: Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes) publication-title: Biochem. Soc. Trans. doi: 10.1042/BST20120265 – volume: 29 start-page: 167 year: 2019 end-page: 174 ident: CR118 article-title: Evaluation and reduction of CRISPR off-target cleavage events publication-title: Nucleic Acid Ther. doi: 10.1089/nat.2019.0790 – volume: 40 start-page: 589 year: 2021 end-page: 601 ident: CR91 article-title: Exosomes: a new perspective in EGFR-mutated lung cancer publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-021-09962-6 – volume: 527 start-page: 329 year: 2015 end-page: 335 ident: CR7 article-title: Tumour exosome integrins determine organotropic metastasis publication-title: Nature doi: 10.1038/nature15756 – volume: 20 start-page: 174 year: 2020 end-page: 186 ident: CR31 article-title: A framework for advancing our understanding of cancer-associated fibroblasts publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0238-1 – volume: 5 year: 2014 ident: CR94 article-title: Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2 publication-title: Nat. Commun. doi: 10.1038/ncomms4477 – volume: 177 start-page: 414 year: 2019 end-page: 427.e413 ident: CR53 article-title: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory publication-title: Cell doi: 10.1016/j.cell.2019.02.016 – volume: 8 year: 2017 ident: CR88 article-title: Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23 publication-title: Nat. Commun. doi: 10.1038/ncomms14041 – volume: 114 start-page: E5549 year: 2017 end-page: E5558 ident: CR102 article-title: Structure of human nSMase2 reveals an interdomain allosteric activation mechanism for ceramide generation publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1705134114 – volume: 21 start-page: 5840 year: 2020 ident: CR40 article-title: Exosomes in angiogenesis and anti-angiogenic therapy in cancers publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21165840 – volume: 23 start-page: 1461 year: 2022 ident: CR16 article-title: Tumor-derived exosomes in tumor-induced immune suppression publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms23031461 – volume: 319 start-page: 1244 year: 2008 end-page: 1247 ident: CR72 article-title: Ceramide triggers budding of exosome vesicles into multivesicular endosomes publication-title: Science doi: 10.1126/science.1153124 – volume: 1793 start-page: 1901 year: 2009 end-page: 1916 ident: CR83 article-title: TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2009.09.011 – volume: 200 start-page: 373 year: 2013 end-page: 383 ident: CR4 article-title: Extracellular vesicles: exosomes, microvesicles, and friends publication-title: J. Cell Biol. doi: 10.1083/jcb.201211138 – volume: 470 start-page: 126 year: 2020 end-page: 133 ident: CR13 article-title: Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.11.009 – volume: 177 start-page: 531 year: 2014 end-page: 543 ident: CR20 article-title: Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells publication-title: Clin. Exp. Immunol. doi: 10.1111/cei.12354 – volume: 39 start-page: 664 year: 2020 end-page: 676 ident: CR35 article-title: ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts publication-title: Oncogene doi: 10.1038/s41388-019-1014-0 – volume: 14 start-page: 677 year: 2012 end-page: 685 ident: CR68 article-title: Syndecan-syntenin-ALIX regulates the biogenesis of exosomes publication-title: Nat. Cell Biol. doi: 10.1038/ncb2502 – volume: 11 year: 2021 ident: CR107 article-title: Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma publication-title: Sci. Rep. doi: 10.1038/s41598-021-89655-w – volume: 49 start-page: 838 year: 2016 end-page: 846 ident: CR46 article-title: Exosome-derived microRNAs contribute to prostate cancer chemoresistance publication-title: Int. J. Oncol. doi: 10.3892/ijo.2016.3560 – volume: 219 start-page: e201904113 year: 2020 ident: CR69 article-title: ALIX- and ESCRT-III-dependent sorting of tetraspanins to exosomes publication-title: J. Cell Biol. doi: 10.1083/jcb.201904113 – volume: 9 start-page: 436 year: 2020 ident: CR103 article-title: Inclusion biogenesis, methods of isolation and clinical application of human cellular exosomes publication-title: J. Clin. Med. doi: 10.3390/jcm9020436 – volume: 24 start-page: 35 year: 2014 end-page: 43 ident: CR80 article-title: Tethering the assembly of SNARE complexes publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2013.09.006 – volume: 8 start-page: e001113 year: 2020 ident: CR112 article-title: Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001113 – volume: 464 start-page: 864 year: 2010 end-page: 869 ident: CR58 article-title: Molecular mechanism of multivesicular body biogenesis by ESCRT complexes publication-title: Nature doi: 10.1038/nature08849 – volume: 367 start-page: eaau6977 year: 2020 ident: CR2 article-title: The biology function and biomedical applications of exosomes publication-title: Science doi: 10.1126/science.aau6977 – volume: 4 start-page: 193 year: 2017 end-page: 200 ident: CR117 article-title: Gene editing, gene therapy, and cell xenotransplantation: cell transplantation across species publication-title: Curr. Transpl. Rep. doi: 10.1007/s40472-017-0157-6 – volume: 18 year: 2019 ident: CR44 article-title: Exosomes in the tumor microenvironment as mediators of cancer therapy resistance publication-title: Mol. Cancer doi: 10.1186/s12943-019-0975-5 – volume: 24 start-page: 2076 year: 2019 end-page: 2085 ident: CR129 article-title: Drug repurposing: a promising tool to accelerate the drug discovery process publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2019.06.014 – volume: 22 start-page: 409 year: 2018 end-page: 417 ident: CR42 article-title: Potential roles of tumor-derived exosomes in angiogenesis publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2018.1464141 – volume: 10 year: 2019 ident: CR130 article-title: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A publication-title: Nat. Commun. doi: 10.1038/s41467-019-09387-4 – volume: 15 start-page: 445 year: 2014 end-page: 451 ident: CR126 article-title: Engineering adeno-associated viruses for clinical gene therapy publication-title: Nat. Rev. Genet. doi: 10.1038/nrg3742 – volume: 67 start-page: 3 year: 2017 end-page: 10 ident: CR12 article-title: Exosomes: key mediators of metastasis and pre-metastatic niche formation publication-title: Semin. Cell Dev. Biol. doi: 10.1016/j.semcdb.2017.01.004 – volume: 70 start-page: 9621 year: 2010 end-page: 9630 ident: CR33 article-title: Cancer exosomes trigger fibroblast to myofibroblast differentiation publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-1722 – volume: 176 start-page: 1375 year: 2006 end-page: 1385 ident: CR22 article-title: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function publication-title: J. Immunol. doi: 10.4049/jimmunol.176.3.1375 – volume: 16 start-page: 1196 year: 2018 end-page: 1204 ident: CR34 article-title: Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFbeta signaling publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-17-0784 – volume: 323 start-page: 474 year: 2009 end-page: 477 ident: CR79 article-title: Membrane fusion: grappling with SNARE and SM proteins publication-title: Science doi: 10.1126/science.1161748 – volume: 28 start-page: 862 year: 2018 end-page: 864 ident: CR98 article-title: Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth publication-title: Cell Res. doi: 10.1038/s41422-018-0060-4 – volume: 31 start-page: 317 year: 2017 end-page: 334 ident: CR120 article-title: Adeno-associated virus (AAV) as a vector for gene therapy publication-title: BioDrugs doi: 10.1007/s40259-017-0234-5 – volume: 7 start-page: 51515 year: 2016 end-page: 51524 ident: CR82 article-title: YKT6 expression, exosome release, and survival in non-small cell lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.9862 – volume: 53 start-page: 697 year: 2021 end-page: 706 ident: CR62 article-title: STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer publication-title: Acta Biochim. Biophys. Sin. (Shanghai) doi: 10.1093/abbs/gmab038 – volume: 16 start-page: 1798 year: 2018 end-page: 1808 ident: CR37 article-title: Exosomes from HNSCC promote angiogenesis through reprogramming of endothelial cells publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-18-0358 – volume: 126 start-page: 5553 year: 2013 end-page: 5565 ident: CR66 article-title: Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles publication-title: J. Cell Sci. – volume: 6 year: 2016 ident: CR19 article-title: Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets publication-title: Sci. Rep. doi: 10.1038/srep20254 – volume: 6 start-page: 550 year: 2020 end-page: 558 ident: CR55 article-title: Exosomal PD-L1: roles in tumor progression and immunotherapy publication-title: Trends Cancer doi: 10.1016/j.trecan.2020.03.002 – volume: 11 start-page: 316 year: 2015 end-page: 318 ident: CR122 article-title: Small molecule-triggered Cas9 protein with improved genome-editing specificity publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio.1793 – volume: 284 start-page: 34211 year: 2009 end-page: 34222 ident: CR86 article-title: Microenvironmental pH is a key factor for exosome traffic in tumor cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.041152 – volume: 74 start-page: 66 year: 2018 end-page: 77 ident: CR57 article-title: Biogenesis and function of ESCRT-dependent extracellular vesicles publication-title: Semin. Cell Dev. Biol. doi: 10.1016/j.semcdb.2017.08.022 – volume: 67 start-page: 5162 year: 2007 end-page: 5171 ident: CR60 article-title: Inhibition of tumor growth and metastasis by depletion of vesicular sorting protein Hrs: its regulatory role on E-cadherin and beta-catenin publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-2756 – volume: 12 start-page: 19 year: 2010 end-page: 30 ident: CR76 article-title: Rab27a and Rab27b control different steps of the exosome secretion pathway publication-title: Nat. Cell Biol. doi: 10.1038/ncb2000 – volume: 34 start-page: 184 year: 2016 end-page: 191 ident: CR123 article-title: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 publication-title: Nat. Biotechnol. doi: 10.1038/nbt.3437 – volume: 12 year: 2021 ident: CR101 article-title: A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis publication-title: Nat. Commun. doi: 10.1038/s41467-021-25990-w – volume: 35 start-page: 169 year: 2005 end-page: 173 ident: CR15 article-title: Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis publication-title: Blood Cells Mol. Dis. doi: 10.1016/j.bcmd.2005.07.001 – volume: 9 start-page: 95 year: 2018 end-page: 106 ident: CR75 article-title: New insights into the function of Rab GTPases in the context of exosomal secretion publication-title: Small GTPases doi: 10.1080/21541248.2016.1264352 – volume: 16 start-page: 582 year: 2016 end-page: 598 ident: CR32 article-title: The biology and function of fibroblasts in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.73 – volume: 359 start-page: 1350 year: 2018 end-page: 1355 ident: CR49 article-title: Cancer immunotherapy using checkpoint blockade publication-title: Science doi: 10.1126/science.aar4060 – volume: 31 start-page: 157 year: 2021 end-page: 177 ident: CR96 article-title: RAB31 marks and controls an ESCRT-independent exosome pathway publication-title: Cell Res. doi: 10.1038/s41422-020-00409-1 – volume: 560 start-page: 382 year: 2018 end-page: 386 ident: CR52 article-title: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response publication-title: Nature doi: 10.1038/s41586-018-0392-8 – volume: 5 start-page: 986 year: 2013 end-page: 996 ident: CR78 article-title: Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin publication-title: Cell Rep. doi: 10.1016/j.celrep.2013.10.019 – volume: 59 start-page: 62 year: 2020 end-page: 72 ident: CR81 article-title: Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer publication-title: Mol. Carcinog. doi: 10.1002/mc.23129 – volume: 7 year: 2016 ident: 856_CR59 publication-title: Nat. Commun. doi: 10.1038/ncomms13588 – volume: 1258 start-page: 189 year: 2020 ident: 856_CR9 publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-030-43085-6_13 – volume: 31 start-page: 157 year: 2021 ident: 856_CR96 publication-title: Cell Res. doi: 10.1038/s41422-020-00409-1 – volume: 74 start-page: 103 year: 2016 ident: 856_CR11 publication-title: Adv. Clin. Chem. doi: 10.1016/bs.acc.2015.12.005 – volume: 367 start-page: eaau6977 year: 2020 ident: 856_CR2 publication-title: Science doi: 10.1126/science.aau6977 – volume: 391 start-page: 111983 year: 2020 ident: 856_CR36 publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2020.111983 – volume: 464 start-page: 864 year: 2010 ident: 856_CR58 publication-title: Nature doi: 10.1038/nature08849 – volume: 11 start-page: 611081 year: 2021 ident: 856_CR61 publication-title: Front. Oncol. doi: 10.3389/fonc.2021.611081 – volume: 176 start-page: 1375 year: 2006 ident: 856_CR22 publication-title: J. Immunol. doi: 10.4049/jimmunol.176.3.1375 – volume: 408 start-page: 73 year: 2017 ident: 856_CR105 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2017.08.020 – volume: 126 start-page: 5553 year: 2013 ident: 856_CR66 publication-title: J. Cell Sci. – volume: 197 start-page: 407 year: 2012 ident: 856_CR70 publication-title: J. Cell Biol. doi: 10.1083/jcb.201110031 – volume: 4 start-page: 193 year: 2017 ident: 856_CR117 publication-title: Curr. Transpl. Rep. doi: 10.1007/s40472-017-0157-6 – volume: 9 start-page: 1085 year: 2010 ident: 856_CR39 publication-title: Mol. Cell Proteom. doi: 10.1074/mcp.M900381-MCP200 – volume: 9 start-page: 1703244 year: 2020 ident: 856_CR127 publication-title: J. Extracell. Vesicles doi: 10.1080/20013078.2019.1703244 – volume: 15 start-page: 445 year: 2014 ident: 856_CR126 publication-title: Nat. Rev. Genet. doi: 10.1038/nrg3742 – volume: 10 start-page: 472 year: 2020 ident: 856_CR45 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00472 – volume: 545 start-page: 495 year: 2017 ident: 856_CR133 publication-title: Nature doi: 10.1038/nature22396 – volume: 527 start-page: 329 year: 2015 ident: 856_CR7 publication-title: Nature doi: 10.1038/nature15756 – volume: 319 start-page: 1244 year: 2008 ident: 856_CR72 publication-title: Science doi: 10.1126/science.1153124 – volume: 49 start-page: 838 year: 2016 ident: 856_CR46 publication-title: Int. J. Oncol. doi: 10.3892/ijo.2016.3560 – volume: 41 start-page: 245 year: 2013 ident: 856_CR17 publication-title: Biochem. Soc. Trans. doi: 10.1042/BST20120265 – volume: 19 start-page: 539 year: 2019 ident: 856_CR132 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0167-y – volume: 290 start-page: 24534 year: 2015 ident: 856_CR99 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M115.679217 – volume: 9 start-page: e2103245 year: 2022 ident: 856_CR111 publication-title: Adv. Sci. (Weinh.) – volume: 52 start-page: 200 year: 2021 ident: 856_CR29 publication-title: Arch. Med. Res. doi: 10.1016/j.arcmed.2020.10.018 – volume: 11 start-page: e12218 year: 2022 ident: 856_CR134 publication-title: J. Extracell. Vesicles doi: 10.1002/jev2.12218 – volume: 74 start-page: 66 year: 2018 ident: 856_CR57 publication-title: Semin. Cell Dev. Biol. doi: 10.1016/j.semcdb.2017.08.022 – volume: 6 start-page: e1362527 year: 2017 ident: 856_CR25 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1362527 – volume: 11 year: 2021 ident: 856_CR107 publication-title: Sci. Rep. doi: 10.1038/s41598-021-89655-w – volume: 9 year: 2018 ident: 856_CR10 publication-title: Nat. Commun. doi: 10.1038/s41467-018-07810-w – volume: 10 year: 2019 ident: 856_CR130 publication-title: Nat. Commun. doi: 10.1038/s41467-019-09387-4 – volume: 10 year: 2019 ident: 856_CR110 publication-title: Nat. Commun. doi: 10.1038/s41467-019-09387-4 – volume: 35 start-page: 169 year: 2005 ident: 856_CR15 publication-title: Blood Cells Mol. Dis. doi: 10.1016/j.bcmd.2005.07.001 – volume: 2014 start-page: 179486 year: 2014 ident: 856_CR30 publication-title: Biomed. Res. Int. doi: 10.1155/2014/179486 – volume: 8 year: 2018 ident: 856_CR106 publication-title: Sci. Rep. doi: 10.1038/s41598-018-26411-7 – volume: 165 start-page: 272 year: 2016 ident: 856_CR50 publication-title: Cell doi: 10.1016/j.cell.2016.03.031 – volume: 22 start-page: 6234 year: 2021 ident: 856_CR6 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22126234 – volume: 35 start-page: 10773 year: 2014 ident: 856_CR47 publication-title: Tumour Biol. doi: 10.1007/s13277-014-2377-z – volume: 37 start-page: 12169 year: 2016 ident: 856_CR27 publication-title: Tumour Biol. doi: 10.1007/s13277-016-5071-5 – volume: 31 start-page: 317 year: 2017 ident: 856_CR120 publication-title: BioDrugs doi: 10.1007/s40259-017-0234-5 – volume: 11 start-page: 316 year: 2015 ident: 856_CR122 publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio.1793 – volume: 24 start-page: 2076 year: 2019 ident: 856_CR129 publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2019.06.014 – volume: 13 year: 2014 ident: 856_CR41 publication-title: Mol. Cancer doi: 10.1186/1476-4598-13-88 – volume: 187 start-page: 481 year: 2021 ident: 856_CR109 publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2021.07.110 – volume: 10 start-page: 1470 year: 2008 ident: 856_CR38 publication-title: Nat. Cell. Biol. doi: 10.1038/ncb1800 – volume: 1870 start-page: 123 year: 2018 ident: 856_CR43 publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2018.07.003 – volume: 58 start-page: 2118 year: 2021 ident: 856_CR63 publication-title: Mol. Neurobiol. doi: 10.1007/s12035-020-02231-7 – volume: 18 start-page: 41 year: 2019 ident: 856_CR128 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.168 – volume: 20 start-page: 174 year: 2020 ident: 856_CR31 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0238-1 – volume: 39 start-page: 664 year: 2020 ident: 856_CR35 publication-title: Oncogene doi: 10.1038/s41388-019-1014-0 – volume: 57 start-page: 24 year: 2015 ident: 856_CR97 publication-title: Adv. Biol. Regul. doi: 10.1016/j.jbior.2014.10.002 – volume: 78 start-page: 4586 year: 2018 ident: 856_CR28 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-3841 – volume: 49 start-page: 325 year: 2021 ident: 856_CR113 publication-title: Artif. Cells Nanomed. Biotechnol. doi: 10.1080/21691401.2021.1902337 – volume: 4 start-page: 27066 year: 2015 ident: 856_CR1 publication-title: J. Extracell. Vesicles doi: 10.3402/jev.v4.27066 – volume: 48 start-page: 417 year: 2018 ident: 856_CR51 publication-title: Immunity doi: 10.1016/j.immuni.2018.03.007 – volume: 67 start-page: 3 year: 2017 ident: 856_CR12 publication-title: Semin. Cell Dev. Biol. doi: 10.1016/j.semcdb.2017.01.004 – volume: 214 start-page: 197 year: 2016 ident: 856_CR95 publication-title: J. Cell Biol. doi: 10.1083/jcb.201601025 – volume: 7 start-page: 51515 year: 2016 ident: 856_CR82 publication-title: Oncotarget doi: 10.18632/oncotarget.9862 – volume: 30 start-page: 3481 year: 2011 ident: 856_CR56 publication-title: Embo J. doi: 10.1038/emboj.2011.286 – volume: 114 start-page: E5549 year: 2017 ident: 856_CR102 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1705134114 – volume: 54 start-page: 131 year: 2019 ident: 856_CR90 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.02.004 – volume: 447 start-page: 48 year: 2019 ident: 856_CR116 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.01.017 – volume: 16 start-page: 582 year: 2016 ident: 856_CR32 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.73 – volume: 26 start-page: 2380 year: 2021 ident: 856_CR124 publication-title: Molecules doi: 10.3390/molecules26082380 – volume: 28 start-page: 862 year: 2018 ident: 856_CR98 publication-title: Cell Res. doi: 10.1038/s41422-018-0060-4 – volume: 177 start-page: 531 year: 2014 ident: 856_CR20 publication-title: Clin. Exp. Immunol. doi: 10.1111/cei.12354 – volume: 58 start-page: 575 year: 2015 ident: 856_CR92 publication-title: Mol. Cell. doi: 10.1016/j.molcel.2015.04.028 – volume: 13 start-page: 2583 year: 2017 ident: 856_CR21 publication-title: Future Oncol. doi: 10.2217/fon-2017-0343 – volume: 22 start-page: 409 year: 2018 ident: 856_CR42 publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2018.1464141 – volume: 29 start-page: 167 year: 2019 ident: 856_CR118 publication-title: Nucleic Acid Ther. doi: 10.1089/nat.2019.0790 – volume: 177 start-page: 414 year: 2019 ident: 856_CR53 publication-title: Cell doi: 10.1016/j.cell.2019.02.016 – volume: 7 year: 2018 ident: 856_CR18 publication-title: Oncogenesis doi: 10.1038/s41389-017-0022-6 – volume: 113 start-page: 609 year: 2022 ident: 856_CR108 publication-title: Cancer Sci. doi: 10.1111/cas.15225 – volume: 23 start-page: 1461 year: 2022 ident: 856_CR16 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms23031461 – volume: 52 start-page: 110 year: 2016 ident: 856_CR65 publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2015.09.046 – volume: 5 start-page: 986 year: 2013 ident: 856_CR78 publication-title: Cell Rep. doi: 10.1016/j.celrep.2013.10.019 – volume: 9 start-page: 436 year: 2020 ident: 856_CR103 publication-title: J. Clin. Med. doi: 10.3390/jcm9020436 – volume: 10 start-page: 513 year: 2009 ident: 856_CR74 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm2728 – volume: 470 start-page: 126 year: 2020 ident: 856_CR13 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.11.009 – volume: 34 start-page: 184 year: 2016 ident: 856_CR123 publication-title: Nat. Biotechnol. doi: 10.1038/nbt.3437 – volume: 4 start-page: eaar2766 year: 2018 ident: 856_CR54 publication-title: Sci. Adv. doi: 10.1126/sciadv.aar2766 – volume: 284 start-page: 34211 year: 2009 ident: 856_CR86 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.041152 – volume: 12 start-page: 341 year: 2011 ident: 856_CR121 publication-title: Nat. Rev. Genet. doi: 10.1038/nrg2988 – volume: 92 start-page: 10733 year: 2020 ident: 856_CR115 publication-title: Anal. Chem. doi: 10.1021/acs.analchem.0c02006 – volume: 200 start-page: 373 year: 2013 ident: 856_CR4 publication-title: J. Cell Biol. doi: 10.1083/jcb.201211138 – volume: 79 start-page: 4557 year: 2019 ident: 856_CR14 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3962 – volume: 14 start-page: 677 year: 2012 ident: 856_CR68 publication-title: Nat. Cell Biol. doi: 10.1038/ncb2502 – volume: 12 year: 2021 ident: 856_CR101 publication-title: Nat. Commun. doi: 10.1038/s41467-021-25990-w – volume: 9 start-page: 95 year: 2018 ident: 856_CR75 publication-title: Small GTPases doi: 10.1080/21541248.2016.1264352 – volume: 18 year: 2019 ident: 856_CR44 publication-title: Mol. Cancer doi: 10.1186/s12943-019-0975-5 – volume: 1793 start-page: 1901 year: 2009 ident: 856_CR83 publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2009.09.011 – volume: 24 start-page: 630 year: 2018 ident: 856_CR71 publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.06.066 – volume: 6 start-page: 550 year: 2020 ident: 856_CR55 publication-title: Trends Cancer doi: 10.1016/j.trecan.2020.03.002 – volume: 24 start-page: 35 year: 2014 ident: 856_CR80 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2013.09.006 – volume: 387 start-page: 61 year: 2017 ident: 856_CR84 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.01.043 – volume: 6 start-page: 1368823 year: 2017 ident: 856_CR24 publication-title: J. Extracell. Vesicles doi: 10.1080/20013078.2017.1368823 – volume: 60 start-page: 9 year: 2019 ident: 856_CR73 publication-title: J. Lipid Res. doi: 10.1194/jlr.R084343 – volume: 16 start-page: 1196 year: 2018 ident: 856_CR34 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-17-0784 – volume: 35 start-page: 206 year: 2020 ident: 856_CR131 publication-title: J. Clin. Apher. doi: 10.1002/jca.21781 – volume: 74 start-page: 5758 year: 2014 ident: 856_CR77 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-3512 – volume: 8 year: 2017 ident: 856_CR88 publication-title: Nat. Commun. doi: 10.1038/ncomms14041 – volume: 219 start-page: e201904113 year: 2020 ident: 856_CR69 publication-title: J. Cell Biol. doi: 10.1083/jcb.201904113 – volume: 108 start-page: 1803 year: 2017 ident: 856_CR100 publication-title: Cancer Sci. doi: 10.1111/cas.13310 – volume: 5 year: 2014 ident: 856_CR94 publication-title: Nat. Commun. doi: 10.1038/ncomms4477 – volume: 21 start-page: 5840 year: 2020 ident: 856_CR40 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21165840 – volume: 16 start-page: 299 year: 2015 ident: 856_CR125 publication-title: Nat. Rev. Genet. doi: 10.1038/nrg3899 – volume: 560 start-page: 382 year: 2018 ident: 856_CR52 publication-title: Nature doi: 10.1038/s41586-018-0392-8 – volume: 145 start-page: 732 year: 2011 ident: 856_CR87 publication-title: Cell doi: 10.1016/j.cell.2011.03.054 – volume: 8 start-page: 727 year: 2019 ident: 856_CR3 publication-title: Cells doi: 10.3390/cells8070727 – volume: 70 start-page: 9621 year: 2010 ident: 856_CR33 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-1722 – volume: 6 start-page: eaba5210 year: 2020 ident: 856_CR104 publication-title: Sci. Adv. doi: 10.1126/sciadv.aba5210 – volume: 67 start-page: 5162 year: 2007 ident: 856_CR60 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-2756 – volume: 80 start-page: 2969 year: 2020 ident: 856_CR89 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-19-3682 – volume: 9 start-page: 861 year: 2020 ident: 856_CR8 publication-title: Cells doi: 10.3390/cells9040861 – volume: 15 year: 2015 ident: 856_CR26 publication-title: BMC Cancer doi: 10.1186/s12885-015-2025-z – volume: 16 start-page: 1798 year: 2018 ident: 856_CR37 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-18-0358 – volume: 1773 start-page: 1116 year: 2007 ident: 856_CR23 publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2007.04.015 – volume: 37 start-page: 3399 year: 2021 ident: 856_CR114 publication-title: Langmuir doi: 10.1021/acs.langmuir.0c03613 – volume: 18 year: 2019 ident: 856_CR5 publication-title: Mol. Cancer doi: 10.1186/s12943-019-0991-5 – volume: 278 start-page: 12513 year: 2003 ident: 856_CR67 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M210843200 – volume: 7 year: 2017 ident: 856_CR64 publication-title: Sci. Rep. doi: 10.1038/srep42961 – volume: 12 start-page: 19 year: 2010 ident: 856_CR76 publication-title: Nat. Cell Biol. doi: 10.1038/ncb2000 – volume: 8 start-page: e001113 year: 2020 ident: 856_CR112 publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001113 – volume: 6 year: 2016 ident: 856_CR19 publication-title: Sci. Rep. doi: 10.1038/srep20254 – volume: 36 start-page: 5369 year: 2017 ident: 856_CR48 publication-title: Oncogene doi: 10.1038/onc.2017.134 – volume: 59 start-page: 62 year: 2020 ident: 856_CR81 publication-title: Mol. Carcinog. doi: 10.1002/mc.23129 – volume: 40 start-page: 589 year: 2021 ident: 856_CR91 publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-021-09962-6 – volume: 5 start-page: 1159 year: 2013 ident: 856_CR93 publication-title: Cell Rep. doi: 10.1016/j.celrep.2013.10.050 – volume: 11 start-page: 2150 year: 2021 ident: 856_CR119 publication-title: Acta Pharm. Sin. B doi: 10.1016/j.apsb.2021.05.020 – volume: 10 start-page: e12146 year: 2021 ident: 856_CR85 publication-title: J. Extracell. Vesicles doi: 10.1002/jev2.12146 – volume: 53 start-page: 697 year: 2021 ident: 856_CR62 publication-title: Acta Biochim. Biophys. Sin. (Shanghai) doi: 10.1093/abbs/gmab038 – volume: 359 start-page: 1350 year: 2018 ident: 856_CR49 publication-title: Science doi: 10.1126/science.aar4060 – volume: 323 start-page: 474 year: 2009 ident: 856_CR79 publication-title: Science doi: 10.1126/science.1161748 |
| SSID | ssj0025474 |
| Score | 2.5380552 |
| SecondaryResourceType | review_article |
| Snippet | Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor... |
| SourceID | nrf pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1379 |
| SubjectTerms | 101/47 42/89 631/67/1059/602 631/67/327 96/44 Antitumor activity Antitumor agents Autocrine signalling Biomedical and Life Sciences Biomedicine Cancer Cancer therapies Chemotherapy Dialysis Drug resistance Exosomes Exosomes - pathology Humans Immune clearance Immune response Immunosuppressive agents Immunotherapy Invasiveness Medical Biochemistry Molecular Medicine Neoplasms - pathology Paracrine signalling Patients Review Review Article Stem Cells Tumor Microenvironment Tumors 생화학 |
| SummonAdditionalLinks | – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB71ISEuCFoegYKMQFwgYuPYcXJcIaqyUrnQot6s-EVX7cYou1u1_56x84CFgoQUKQePpYlnPP4m8zDA67xgTgiuUm61SRmvTVoawdLaCoe2keuuQu74c3F0ymZn_GwL6FALE5P2Y0vLaKaH7LD3y4xSEdJlaRpQQpHm27AbWrWjbu9Op7Mvs9HN4kywvjxmkpe3zNw4grab1t2GLv9MkvwtUhoPoMP7cK9HjmTa8foAtmyzB_tT_Ay_uCFvSMzljD_J9-DOcR8y34evJzHX2xoyb87nKmZoEe_Iar3wbWpQAa9wzF77pV_YJanxIY2_spfkl9Is4qNlIYhwiQ560j6E08OPJx-O0v4yhVQjIlulNqcqYLtJpWxpHOXa1eiOKK7LOle1dc4hGML1sTW6lGJS6RKRkmJGcGY0OjWPYKfxjX0CpDKZ4mXJVUENq0VZOaqZQ0NZZM5mRiWQDesrdd9pPFx4cSljxDsvZScTiTKRUSYyT-DtOOd712fjn9SvUGzyQs9laI8d3t-8vGglOgGfQhtmjm5_kcDBIFbZ78ylpCJcZR7iuQm8HIdxT4VASd1Yvw40GRcVQj-WwONOC0am8iILXnOVgNjQj5EgMLQ50szPY9_uiudoLkUC7wZN-snW37_16f-RP4O7NOp6SIM7gJ1Vu7bPETet1It-o_wAe9ASog priority: 102 providerName: Springer Nature |
| Title | Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer |
| URI | https://link.springer.com/article/10.1038/s12276-022-00856-3 https://www.ncbi.nlm.nih.gov/pubmed/36117219 https://www.proquest.com/docview/2721464645 https://www.proquest.com/docview/2715791254 https://pubmed.ncbi.nlm.nih.gov/PMC9534887 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002881580 |
| Volume | 54 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Experimental and Molecular Medicine, 2022, 54(0), , pp.1-11 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-xTUK8INj4CIzKCMQLWGsSO06eUKk2jUqbEGyob1b8xaqtyWjaCf57zk7aUj4mRYoUO5KT-_n8O9_5DuB1mjEnBFeUW20o46WhuRGMllY41I1ctyfkTk6z43M2GvNxt-HWdGGVS50YFLWptd8jP0iEL0Ht_XDvr79TXzXKe1e7EhpbsONTl3lUi_Ha4OIsZGGOkWLQFNet7tBMP80PGnwofPhtQj3rwPaNhWmrmrl_cc6_Qyf_8J-GZenoAdzv-CQZtAB4CHdstQt7gwpt6elP8oaECM-wdb4Ld086R_oefD0LEeDWkEl1MVEhbovUjswX03pGDcLyBtvsj7qpp7YhJV6kqm_sFfntwBapg74hyHuJ9uiZPYLzo8Oz4THtSixQjTxtTm2aKM_4-oWyuXEJ165EI0VxnZepKq1zDikS_h9boqEp-oXOkT8pZgRnRqOp8xi2q7qyT4EUJlY8z7nKEsNKkRcu0cyh-sxiZ2OjIoiX_1fqLv-4L4NxJYMfPM1lKxOJMpFBJjKN4O3qnes2-8atvV-h2OSlnkifNNvfv9XycibRNPjokzPzPsuyCPaXYpXdfG3kGl0RvFw140zz7pOysvXC94m5KJAQsgietChYDQrR5W3pIgKxgY9VBz-gzZZqchGyeRc8RSUqIni3RNJ6WP__1me3f8VzuJcEbPtguH3Yns8W9gWyp7nqhSnSg53BYPRlhPcPh6efPuPTYTbshR2JX8bkGlk |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VIgEvCFqOQAEjjhewujkcJw8IVUC1S7t92qJ9c-OLrtpNyh6F_il-I2Mn2WU5-lYpUqTYkZzM5_E3nvEMwMs4TSznTFJmlKYJKzTNNE9oYbhF3chUfUKuf5B2D5PPQzZcg5_tWRgXVtnqRK-odaXcHvl2xF0JaueHe3_2jbqqUc672pbQqGGxZy6-o8k2fdf7iPJ9FUW7nwYfurSpKkAVUpMZNXEkHcnp5NJk2kZM2QJ5uWQqK2JZGGstsoKMpaZA24p3cpUhZZCJ5izRirsqEajyr-PC23HGHh8uDTyW-KzPIVIaGuM62RzS6cTZ9hQfchfuG1HHcrB9ZSG8Vk7svzju36Gaf_hr_TK4ewduN_yV7NSAuwtrptyAzZ0SbffxBXlNfESp36rfgBv9xnG_CV8GPuLcaDIqj0fSx4mRypLZfFxNqMZpcI5t5kc1rcZmSgq8SFmdm1Py2wExUnn9RpBnE-XQOrkHh1fy8-_DelmV5iGQXIeSZRmTaaSTgme5jVRiUV2noTWhlgGE7f8Vqsl37spunArvd48zUctEoEyEl4mIA3izeOeszvZxae8XKDZxokbCJel296-VOJkINEV6Lhk06yRpGsBWK1bR6IepWKI5gOeLZpzZzl1TlKaauz4h4zkS0CSABzUKFoNCdDnbPQ-Ar-Bj0cENaLWlHB377OE5i1Fp8wDetkhaDuv_3_ro8q94Bje7g_6-2O8d7D2GW5HHuQvE24L12WRuniBzm8mnfroQOLrq-fkLBthSXg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VrVTxgqDlCBQw4niBaDeH4-QBoUK76lK6qlCL-ubGF121m5Q9Cv1r_DrGzlGWo2-VVoq0diQn8834m8x4BuBFlMSGMSp8qqXyY5orP1Us9nPNDNpGKqsTcrvDZPsg_nhID5fgZ3MWxqZVNjbRGWpVSvuNvBsy24LaxuG6pk6L2Nvsvzv75tsOUjbS2rTTqCCyoy--o_s2fTvYRFm_DMP-1v6Hbb_uMOBLpCkzX0ehsISnlwmdKhNSaXLk6ILKNI9Ero0xyBBSmugc_SzWy2SK9EHEitFYSWY7RqD5X2bWK-rA8vut4d7n1t2jsasBHSDB8SPcNesjO70o7U7xT2aTf0Pfch4cX9gWbxQT8y_G-3fi5h_RW7cp9m_DrZrNko0KfndgSRersLZRoCc_viCviMsvdR_uV2Fltw7jr8GXfZd_rhUZFccj4bLGSGnIbD4uJ75CpTjHMf2jnJZjPSU5_khRnutT8ttxMVI6a0eQdRNpsTu5CwfX8vrvQacoC_0ASKYCQdOUiiRUcc7SzIQyNmi8k8DoQAkPgub9cllXP7dNOE65i8JHKa9kwlEm3MmERx68bu85q2p_XDn7OYqNn8gRtyW77fVryU8mHB2TgS0NTXtxkniw3oiV19Ziyi-x7cGzdhj13AZv8kKXczsnoCxDOhp7cL9CQbsoRJf15DMP2AI-2gl2QYsjxejY1RLPaIQmnHnwpkHS5bL-_6wPr36Kp7CCusk_DYY7j-Bm6GBus_LWoTObzPVjpHEz8aTWFwJH162ivwDG9Ff5 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+inhibition+of+tumor-derived+exosomes+as+a+novel+therapeutic+option+for+cancer&rft.jtitle=Experimental+%26+molecular+medicine&rft.au=Li+Ye&rft.au=Chen+Zhuo-Kun&rft.au=Duan+Xu&rft.au=Zhang+He-Jing&rft.date=2022-09-01&rft.pub=%EC%83%9D%ED%99%94%ED%95%99%EB%B6%84%EC%9E%90%EC%83%9D%EB%AC%BC%ED%95%99%ED%9A%8C&rft.issn=1226-3613&rft.eissn=2092-6413&rft.spage=1&rft.epage=11&rft_id=info:doi/10.1038%2Fs12276-022-00856-3&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10050466 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-6413&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-6413&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-6413&client=summon |